Ansgar Klimke

Prof. Ansgar Klimke

vitos Klinikum Hochtaunus / University of Duesseldorf
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2014 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
UVUrsula Voss
Ursula Voss
RHRomain Holzmann
Romain Holzmann
AHAllan Hobson
Allan Hobson
WPWalter Paulus
Walter Paulus
JKJudith Koppehele-Gossel
Judith Koppehele-Gossel
MNMichael A Nitsche
Michael A Nitsche

26 April 1999 in Psychiatry Research: Neuroimaging
Verified
Journal Article
Closed access
AKAnsgar Klimke
Ansgar Klimke
RLR Larisch
R Larisch
AJA Janz
A Janz
HVH Vosberg
H Vosberg
HMH W Müller-Gärtner
H W Müller-Gärtner
WGW Gaebel
W Gaebel

3 July 2013 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
ACAnja Cerovecki
Anja Cerovecki
RMRichard Musil
Richard Musil
AKAnsgar Klimke
Ansgar Klimke
FSFlorian Seemüller
Florian Seemüller
EHEkkehard Haen
Ekkehard Haen
MRMichael Riedel
Michael Riedel

1 May 1997 in NeuroImage
Verified
Journal Article
Closed access
RLR. Larisch
R. Larisch
AKAnsgar Klimke
Ansgar Klimke
HVH. Vosberg
H. Vosberg
SLS. Löffler
S. Löffler
WGW. Gaebel
W. Gaebel
HMH.-W. Müller-Gärtner
H.-W. Müller-Gärtner

21 January 2005 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
DND. Naber
D. Naber
MRM. Riedel
M. Riedel
AKAnsgar Klimke
Ansgar Klimke
EVE.‐U. Vorbach
E.‐U. Vorbach
MLM. Lambert
M. Lambert
RDR. W. Dittmann
R. W. Dittmann

1 October 2005 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
KFKarin Fehsel
Karin Fehsel
SLStefan Loeffler
Stefan Loeffler
KKKlaus Krieger
Klaus Krieger
UHUwe Henning
Uwe Henning
MAMarkus Agelink
Markus Agelink
AKAnsgar Klimke
Ansgar Klimke
The present study examined cellular effects of the atypical antipsychotic drug clozapine on blood cells of treated patients with and without clozapine-induced agranulocytosis (CA). Blood from one patient who commenced clozapine treatment was examined at weekly intervals for 128 days. Olanzapine-treated (n = 5) and polymedicated (n = 14) schizophrenic patients, as well as healthy subjects (n = 19) and septic shock patients (n = 8), were studied for comparison. We observed dramatically increased numbers of native neutrophils stained for superoxide anion production (P ≤ 0.005, n = 10) and significantly elevated expression levels of the proapoptotic genes p53 (P ≤ 0.020), bax α (P ≤ 0.001), and bik (P ≤ 0.002) in all tested non-CA patients (n = 19) and CA patients (n = 4). In non-CA patients, the expression of these genes did not correlate to the percentage of apoptotic neutrophils (2.0% ± 1.3%), but in CA patients about 37% of the neutrophils show morphologic signs of apoptosis (P ≤ 0.001). Under G-CSF therapy of CA, the number of apoptotic neutrophils and the expression of the proapoptotic genes decreased significantly. In conclusion, high production of reactive oxygen species in neutrophils of clozapine-treated patients, together with increased expression of proapoptotic genes, suggests that neutrophils are predisposed to apoptosis in schizophrenic patients under clozapine therapy. The correlation between drug and proapoptotic markers was highest for clozapine and bax α as well as superoxide anion radicals. This indicates oxidative mitochondrial stress in neutrophils of clozapine-treated patients which probably contributes to the induction of apoptosis and sudden loss of neutrophils and their precursors in CA patients.